TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18294333

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg single dose in CYP2C19*17/*17 subjects
Number of subjects: 17

Group type: COMPARATOR
Intervention: Omeprazole 40 mg single dose in CYP2C19*1/*1 subjects
Number of subjects: 17
Study: 15772362

Group type: EXPERIMENTAL
Intervention: Intensive therapy (IT)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 142
Study: 12517462

Group type: EXPERIMENTAL
Intervention: Radiofrequency lesioning of dorsal root ganglia
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control treatment (local anaesthetics)
Number of subjects: 83
Study: 11138908

Group type: EXPERIMENTAL
Intervention: Standardized academic achievement tests in rural population
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Standardized academic achievement tests in urban population
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Neuropsychological evaluation of children with arithmetic deficits
Number of subjects: 363
Study: 8706775

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily for 2 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg daily for 2 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg for 1 week
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg for 1 week
Number of subjects: 12
Study: 1580340

Group type: EXPERIMENTAL
Intervention: Psychoeducational support group
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study: 31936428

Group type: EXPERIMENTAL
Intervention: Low GI diet (n = 18)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control diet (n = 18)
Number of subjects: 40
Study: 31689118

Group type: COMPARATOR
Intervention: Coffee with 0g MCT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Coffee with 28g MCT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Coffee with 42g MCT
Number of subjects: 10
Study: 28190457

Group type: EXPERIMENTAL
Intervention: Tiered consent and controlled data sharing
Number of subjects: 13000

Group type: EXPERIMENTAL
Intervention: Broad consent and controlled data sharing
Number of subjects: 13000

Group type: EXPERIMENTAL
Intervention: Broad consent and open data sharing
Number of subjects: 13000

Group type: EXPERIMENTAL
Intervention: Overall population-weighted respondents
Number of subjects: 13000

Group type: EXPERIMENTAL
Intervention: Overall participants
Number of subjects: 13000
Study: 25923045

Group type: EXPERIMENTAL
Intervention: Remifentanil at three target‐site concentrations: 1, 2, and 3 ng/ml
Number of subjects: 14

Group type: COMPARATOR
Intervention: Naloxone (6 μg/kg bolus followed by 0.1 μg/kg/min infusion)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Metoclopramide (0.2 mg/kg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Remifentanil before and after metoclopramide administration
Number of subjects: 14
Study: 25798508

Group type: EXPERIMENTAL
Intervention: 12-week group psychotherapy intervention (New Beginnings program)
Number of subjects: 0
Study: 22795863

Group type: EXPERIMENTAL
Intervention: Seal-In liner
Number of subjects: 9

Group type: COMPARATOR
Intervention: Dermo liner
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Both liners
Number of subjects: 9
Study: 20647058

Group type: EXPERIMENTAL
Intervention: Improved medication labels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard labels
Number of subjects: 0
Study: 17470735

Group type: EXPERIMENTAL
Intervention: 2% testosterone in Vanicream (10 mg daily)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo Vanicream
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Both testosterone and placebo
Number of subjects: 150
Study: 15006032

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amnesic patients with extensive medial temporal lobe damage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mild hypoxic patients with selective hippocampal damage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient with thalamic lesions
Number of subjects: 0
Study: 12575232

Group type: EXPERIMENTAL
Intervention: nao-yi-an treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: medicine control group
Number of subjects: 0

Group type: COMPARATOR
Intervention: healthy control group
Number of subjects: 0
Study: 10319667

Group type: EXPERIMENTAL
Intervention: Quadruple therapy (amoxycillin 500 mg t.i.d., metronidazole 500 mg t.i.d., furoxone 100 mg t.i.d. for 5 days during the 3rd week) + ranitidine 300 mg daily for 8 weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Ranitidine 150 mg daily for 12 months
Number of subjects: 51
Study: 7635369

Group type: EXPERIMENTAL
Intervention: Lymphocyte immunotherapy (LI) + Progesterone (P)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Progesterone alone
Number of subjects: 66
Study: 2793265

Group type: EXPERIMENTAL
Intervention: Labetalol (200 mg)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg) plus Nifedipine (10 mg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Both regimens
Number of subjects: 29
Study: 694487

Group type: EXPERIMENTAL
Intervention: Antibiotics plus granulocyte transfusions (1.7‐14.7 X 10(10) granulocytes by 1‐5 daily transfusions, mean 6.6 X 10(10))
Number of subjects: 25

Group type: COMPARATOR
Intervention: Antibiotics alone
Number of subjects: 25
Study: 30829619

Group type: EXPERIMENTAL
Intervention: GDNF (administered every 4 weeks for 80 weeks)
Number of subjects: 41

Group type: COMPARATOR
Intervention: GDNF (after 40 weeks of placebo)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: GDNF/GDNF (Week 80)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo/GDNF (Week 40)
Number of subjects: 41
Study: 28301671

Group type: EXPERIMENTAL
Intervention: BMSCs plus penicillamine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Penicillamine
Number of subjects: 60
Study: 26130141

Group type: EXPERIMENTAL
Intervention: 48 weeks of Peginterferon (Peg‐IFN) alfa‐2a 180 μg/week plus weight-based ribavirin (RBV) 1,000‐1,200 mg/day
Number of subjects: 187

Group type: COMPARATOR
Intervention: 24 weeks of Peginterferon (Peg‐IFN) alfa‐2a 180 μg/week plus weight-based ribavirin (RBV) 1,000‐1,200 mg/day
Number of subjects: 187
Study: 24359229

Group type: EXPERIMENTAL
Intervention: ZRADSQ (Zheng-related atopic dermatitis symptom questionnaire)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: ZRADSQ
Number of subjects: 188
Study: 22084960

Group type: EXPERIMENTAL
Intervention: Cardiac TRUST intervention group
Number of subjects: 38

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 38
Study: 19689237

Group type: EXPERIMENTAL
Intervention: Cognitive training (reasoning and speed of processing)
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Memory training
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Reasoning and speed of processing training
Number of subjects: 3000
Study: 16676701

Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (6 mg/kg body mass)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 15567646

Group type: EXPERIMENTAL
Intervention: Patients who agreed to participate in the survey (consenters)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Patients who declined to participate in the survey (nonconsenters)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Older age (>60 yrs)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Reassuring attitude conveyed by study personnel
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Trust in study personnel
Number of subjects: 52

Group type: COMPARATOR
Intervention: Perception of being a 'guinea pig'
Number of subjects: 52
Study: 10945318

Group type: EXPERIMENTAL
Intervention: RIG200 (6 nmol/min infusion)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sodium nitroprusside (0.06 nmol/min infusion)
Number of subjects: 14
Study: 9076208

Group type: EXPERIMENTAL
Intervention: Coagulase-negative staphylococci (CoNS) cultured from the anterior chamber and vitreous
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Non-S epidermidis CoNS
Number of subjects: 225
Study: 8093340

Group type: EXPERIMENTAL
Intervention: In vivo exposure (IVE)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Vicarious exposure (VE)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: In vivo exposure plus vicarious exposure (IVVE)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Assessment only control
Number of subjects: 48
Study: 2943050

Group type: EXPERIMENTAL
Intervention: High dose ipratropium bromide (200 micrograms three times daily for four weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High dose ipratropium bromide
Number of subjects: 15
Study: 29387936

Group type: EXPERIMENTAL
Intervention: Group cognitive behavioral therapy (CBT) for insomnia
Number of subjects: 51

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 51
Study: 26316089

Group type: EXPERIMENTAL
Intervention: Total Knee Replacement Surgery (TKR)
Number of subjects: 390
Study: 25664657

Group type: EXPERIMENTAL
Intervention: Worsening trajectories of inattention symptoms and delinquency
Number of subjects: 579

Group type: COMPARATOR
Intervention: Stable or improving trajectories of inattention symptoms and delinquency
Number of subjects: 579
Study: 23076383

Group type: EXPERIMENTAL
Intervention: Coadministration of 10-valent pneumococcal conjugate vaccine (PHiD-CV) and tetravalent meningococcal conjugate vaccine (MenACWY-TT)
Number of subjects: 363

Group type: COMPARATOR
Intervention: MenACWY-TT alone
Number of subjects: 363

Group type: COMPARATOR
Intervention: PHiD-CV alone
Number of subjects: 363
Study: 20175039

Group type: EXPERIMENTAL
Intervention: Sprint training program (6 months)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 12
Study: 18239639

Group type: EXPERIMENTAL
Intervention: Increase healthy foods
Number of subjects: 41

Group type: COMPARATOR
Intervention: Reduce high energy-dense foods
Number of subjects: 41
Study: 16627574

Group type: EXPERIMENTAL
Intervention: 7 mg transdermal nicotine patch (NIC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: colour‐matched placebo (PLA)
Number of subjects: 12
Study: 12603713

Group type: EXPERIMENTAL
Intervention: Nasal budesonide (64 microg per nasal cavity b.i.d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 11045912

Group type: EXPERIMENTAL
Intervention: Sildenafil (Viagra) 10-100 mg, taken as needed approximately 1 hour prior to sexual activity
Number of subjects: 233

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study: 9193208

Group type: EXPERIMENTAL
Intervention: Tizanidine hydrochloride (8 or 16 mg)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 1553900

Group type: EXPERIMENTAL
Intervention: Cisplatin plus epirubicin (60 mg/m2 cisplatin + 75 mg/m2 epirubicin)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Cisplatin plus doxorubicin (60 mg/m2 cisplatin + 60 mg/m2 doxorubicin)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Cisplatin plus epirubicin
Number of subjects: 116

Group type: COMPARATOR
Intervention: Cisplatin plus doxorubicin
Number of subjects: 116
Study: 3546154

Group type: EXPERIMENTAL
Intervention: Ofloxacin 200 mg
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg
Number of subjects: 234
Study: 29709061

Group type: EXPERIMENTAL
Intervention: Brief Strategic Family Therapy (BSFT)
Number of subjects: 103
Study: 28280319

Group type: EXPERIMENTAL
Intervention: UMEC/VI 62.5/25 µg
Number of subjects: 494

Group type: COMPARATOR
Intervention: TIO 18 µg
Number of subjects: 494
Study: 26502846

Group type: EXPERIMENTAL
Intervention: Three-dimensional CT reconstruction and cephalometry
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional diagnostic technique
Number of subjects: 58
Study: 23328113

Group type: EXPERIMENTAL
Intervention: Low-n-6 PUFA (L6) intervention
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: High-n-3 PUFA, low-n-6 PUFA (H3-L6) intervention
Number of subjects: 67
Study: 20872225

Group type: EXPERIMENTAL
Intervention: Pueraria mirifica 25 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Pueraria mirifica 50 mg
Number of subjects: 52
Study: 19449756

Group type: EXPERIMENTAL
Intervention: Intervention group (physician/pharmacist collaboration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 0
Study: 17448262

Group type: EXPERIMENTAL
Intervention: Intrauterine levonorgestrel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral progestogens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive pill
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gonadotrophin-releasing hormone (GnRH) analogues
Number of subjects: 0
Study: 14737756

Group type: EXPERIMENTAL
Intervention: New treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study: 12357478

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 80/4.5 microg, two inhalations twice daily (n = 148)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Budesonide 100 microg, two inhalations twice daily (n = 138)
Number of subjects: 286
Study: 9681285

Group type: EXPERIMENTAL
Intervention: DASH dietary patterns
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Recruitment strategies (targeted mailings, mass mailings, community screenings, mass media advertising)
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Financial incentives ($150 to $160 reimbursement)
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Participation willingness
Number of subjects: 459
Study: 8006886

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 3135194

Group type: EXPERIMENTAL
Intervention: Flumazenil 0.1 mg.kg‐1
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Flumazenil 0.2 mg.kg‐1
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30721737

Group type: EXPERIMENTAL
Intervention: Aquablation
Number of subjects: 66

Group type: COMPARATOR
Intervention: TURP
Number of subjects: 66
Study: 28648402

Group type: EXPERIMENTAL
Intervention: Guided graded exercise self-help (GES)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Specialist medical care (SMC) alone (control group)
Number of subjects: 211
Study: 26457155

Group type: EXPERIMENTAL
Intervention: Longitudinal ultrasound curriculum
Number of subjects: 48

Group type: COMPARATOR
Intervention: No longitudinal ultrasound curriculum (Control)
Number of subjects: 48
Study: 23731525

Group type: EXPERIMENTAL
Intervention: Hand hygiene intervention consisting of HH products, training, team training sessions, and reminders.
Number of subjects: 600

Group type: COMPARATOR
Intervention: Usual practice (control group) in 35 DCCs.
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Hand hygiene intervention.
Number of subjects: 600
Study: 20817685

Group type: EXPERIMENTAL
Intervention: Community pharmacist-delivered adherence support service
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 142
Study: 19167078

Group type: EXPERIMENTAL
Intervention: Center point thickness measured by OCT in CRVO participants
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Center point thickness measured by OCT in BRVO participants
Number of subjects: 665
Study: 17121065

Group type: EXPERIMENTAL
Intervention: Barrier-enhancing cosmetic moisturizer with vitamins (niacinamide, panthenol, tocopheryl acetate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cosmetic moisturizer without vitamins
Number of subjects: 0
Study: 15621107

Group type: EXPERIMENTAL
Intervention: Bipolar electrocautery for division of left renal vein branches
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Bipolar electrocautery
Number of subjects: 160
Study: 11762152

Group type: EXPERIMENTAL
Intervention: Oral hormone replacement therapy (n = 19)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Transdermal hormone replacement therapy (n = 18)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Comparison of oral vs transdermal hormone replacement therapy
Number of subjects: 37
Study: 9407675

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg (2 x ED90)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vecuronium 0.1 mg/kg (2 x ED90)
Number of subjects: 60
Study: 8498661

Group type: COMPARATOR
Intervention: Intravenous sufentanil (SIV)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Epidural sufentanil (SEPI)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Epidural fentanyl (FEPI)
Number of subjects: 45
Study: 3367257

Group type: EXPERIMENTAL
Intervention: 6 mg melatonin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29880048

Group type: EXPERIMENTAL
Intervention: Peer-led physical activity intervention (PLAN-A)
Number of subjects: 427

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 427
Study: 29238675

Group type: EXPERIMENTAL
Intervention: Pterygopalatine fossa infiltration with 2% lignocaine and 1:80,000 adrenaline
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control side (non-infiltrated)
Number of subjects: 68
Study: 25684570

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 344

Group type: COMPARATOR
Intervention: UFH+VKA
Number of subjects: 344
Study: 23433534

Group type: EXPERIMENTAL
Intervention: Extended culture for 16-18h (EC group, n=242)
Number of subjects: 479

Group type: COMPARATOR
Intervention: Conventional culture for 2h (control group, n=237)
Number of subjects: 479
Study: 20653677

Group type: EXPERIMENTAL
Intervention: Ciclosporin (5 mg kg(‐1))
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 18662152

Group type: EXPERIMENTAL
Intervention: OL-S-HDF
Number of subjects: 16

Group type: COMPARATOR
Intervention: OL-P-HDF
Number of subjects: 16

Group type: COMPARATOR
Intervention: HF-HD
Number of subjects: 16
Study: 16960164

Group type: EXPERIMENTAL
Intervention: Diet with n-6:n-3 ratio of approximately 3:1 enriched with EPA and DHA
Number of subjects: 258

Group type: COMPARATOR
Intervention: Control diet with n-6:n-3 ratio of 10:1
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Test meal containing 50 g fat
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Avoiding foods high in fat the day before measurement
Number of subjects: 258
Study: 15275751

Group type: EXPERIMENTAL
Intervention: ATC dosing of acetaminophen with codeine (120 mg/12 mg/5 ml) every 4 h for 3 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: PRN dosing of acetaminophen with codeine (120 mg/12 mg/5 ml) every 4 h PRN for 3 days
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ATC dosing of acetaminophen with codeine with nurse coaching (120 mg/12 mg/5 ml) every 4 h for 3 days
Number of subjects: 80
Study: 11404441

Group type: EXPERIMENTAL
Intervention: 1 cycle per degree (cpd) gratings, counterphase-reversed in contrast at either 3.3 or 5.5 Hz with a mask of either the same or orthogonal orientation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adults
Number of subjects: 0
Study: 9405024

Group type: EXPERIMENTAL
Intervention: recombinant human GH (rhGH)
Number of subjects: 32

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 32
Study: 8495774

Group type: EXPERIMENTAL
Intervention: One dose of intranasal nafarelin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two doses of intranasal nafarelin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 3450521

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 30873633

Group type: EXPERIMENTAL
Intervention: Proxeed Plus for 6 months
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Proxeed Plus
Number of subjects: 175
Study: 28240758

Group type: EXPERIMENTAL
Intervention: MIMERACI technique
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional technique (group A)
Number of subjects: 100
Study: 26665290

Group type: EXPERIMENTAL
Intervention: Regimen One: Arm & Hammer Truly Radiant toothpaste and Arm & Hammer Truly Radiant Extra Whitening Spinbrush
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Regimen Two: Arm & Hammer Truly Radiant toothpaste, Arm & Hammer Truly Radiant Extra Whitening Spinbrush, and a whitening booster
Number of subjects: 60

Group type: COMPARATOR
Intervention: Regimen Three: Colgate Cavity Protection toothpaste and an ADA standard manual brush
Number of subjects: 60
Study: 24055212

Group type: EXPERIMENTAL
Intervention: Rotigotine 2 mg/24 h
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Rotigotine 3 mg/24 h
Number of subjects: 284

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study: 21145183

Group type: EXPERIMENTAL
Intervention: Alcohol-attentional bias (alcohol Stroop task)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Impulsive decision-making (delay discounting task)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Impaired inhibitory control (GO-NOGO task)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol-attentional bias and impulsive decision-making
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive measures (alcohol-attentional bias, impulsive decision-making, impaired inhibitory control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Impulsive decision-making and impaired inhibitory control
Number of subjects: 0
Study: 19719796

Group type: EXPERIMENTAL
Intervention: Motivationally Enhanced (ME) treatment plus Nicotine Replacement Therapy (NRT)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Standard Care (SC) treatment plus Nicotine Replacement Therapy (NRT)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: NRT contact
Number of subjects: 444
Study: 17720019

Group type: EXPERIMENTAL
Intervention: Norepinephrine plus dobutamine
Number of subjects: 330

Group type: COMPARATOR
Intervention: Epinephrine
Number of subjects: 330
Study: 15120803

Group type: EXPERIMENTAL
Intervention: Prior angina (n = 111)
Number of subjects: 283

Group type: COMPARATOR
Intervention: No prior angina (n = 172)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Diabetic patients with prior angina
Number of subjects: 283